Clinical support materials

BSH Guidelines 2025 for the 1L Treatment of CLL

A summary of the BSH guidelines for the 1L treatment of CLL, and key efficacy and safety information for CALQUENCE across both fixed and continuous treatment options.

Found this useful? You might also be interested in:

 

CLL Exchange Bite-sized:
Fixed-duration decision
making in 1L CLL.

The CLL Exchange:
Managing Cardiovascular
Comorbidities and Complication
in CLL

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

September 2025 I GB-69434